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Abstract
Background: Older adults with diabetes take fewer steps per day than those without diabetes. The purpose of the
present study was to investigate the association of daily step count with incident diabetes in community-dwelling
70-year-olds.
Methods: This prospective cohort study included N = 3055 community-dwelling 70-year-olds (52% women) who
participated in a health examination in Umeå, Sweden during 2012–2017, and who were free from diabetes at
baseline. Daily step count was measured for 1 week using Actigraph GT3X+ accelerometers. Cases of diabetes were
collected from the Swedish National Patient Register. The dose-response association was evaluated graphically using a
flexible parametric model, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox
regressions.
Results: During a mean follow-up of 2.6 years, diabetes was diagnosed in 81 participants. There was an inverse
nonlinear dose-response association between daily step count and incident diabetes, with a steep decline in risk of
diabetes from a higher daily step count until around 6000 steps/day. From there, the risk decreased at a slower rate
until it leveled off at around 8000 steps/day. A threshold of 4500 steps/day was found to best distinguish participants
with the lowest risk of diabetes, where those taking ≥ 4500 steps/day, had 59% lower risk of diabetes, compared to
those taking fewer steps (HR, 0.41, 95% CI, 0.25–0.66). Adjusting for visceral adipose tissue (VAT) attenuated the
association (HR, 0.64, 95% CI, 0.38–1.06), which was marginally altered after further adjusting for sedentary time,
education and other cardiometabolic risk factors and diseases (HR, 0.58, 95% CI, 0.32–1.05).
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Conclusions: A higher daily step count is associated with lower risk of incident diabetes in community-dwelling 70-
year-olds. The greatest benefits occur at the lower end of the activity range, and much earlier than 10,000 steps/day.
With the limitation of being an observational study, these findings suggest that promoting even a modest increase in
daily step count may help to reduce the risk of diabetes in older adults. Because VAT appears to partly mediate the
association, lifestyle interventions targeting diabetes should apart from promoting physical activity also aim to prevent
and reduce central obesity.
Keywords: Physical activity, Walking, Accelerometry, Metabolic syndrome, Non-communicable disease, Visceral adipose
tissue, Obesity
Background
Diabetes increases the risk of retinopathy, nephropathy,
physical disability, and cardiovascular disease (CVD), as
well as disease-specific and all-cause mortality [1–4]. In
addition, diabetes poses a significant economic burden to
care systems [5]. Today, the prevalence of diabetes is esti-
mated to exceed 460 million people, [6, 7], and despite
some improvements in diabetes-related complications, a
considerable burden persists [8]. Meanwhile, the projected
rise in diabetes prevalence by 25% until 2030 and 51% by
2045 is largely attributed to rapid population ageing [7, 9].
Thus, effective and sustainable strategies for preventing
diabetes among older people should be a priority.
Older people experience increased risk of diabetes due
to complex interactions between genetics, lifestyle and
biological ageing [10]. The ageing process has a negative
effect on β-cell function and leads to increased visceral
adipose tissue (VAT) and loss of muscle mass, which to-
gether with a decline in physical activity (PA) promotes
inflammation and insulin resistance [10, 11]. Lifestyle in-
terventions, focusing on diet and PA, are key compo-
nents in the management and prevention of diabetes
[12, 13], and its effectiveness among middle-aged indi-
viduals has been shown in randomized trials [14, 15].
However, research on older people is needed [16] in
order to develop appropriate and effective strat-
egies which could help healthcare systems to successfully
meet the challenges that will follow the unprecedented
ageing of the world’s population.
Walking is the fundamental unit of locomotion and
the most readily accessible type of PA and exercise, with
a high preference among older people [17]. Self-reported
walking has previously been associated with lower risk
of incident diabetes [18]. However, the use of wearable
devices which can objectively track daily step count is
increasing [19], also in older adults [20]. This trend, to-
gether with the fact that daily step count is an intuitive
metric of PA and something that the general older indi-
vidual can easily comprehend, implies that findings from
such research may have high public health relevance and
translational potential. This could further support the
development of recommendations and policies [21]. In a
recent cross-sectional study, it was found that 70-year-
olds with prevalent diabetes take significantly fewer daily
steps than those free from diabetes [22]. Against this
background, the aim of the present study was to investi-
gate the association of daily step count with incident dia-
betes in a large cohort of community-dwelling 70-year-
old men and women.
Methods
Study design and population
This prospective cohort study was based on the Healthy
Ageing Initiative study (HAI), initiated in May 2012 in
Umeå, a municipality in Northern Sweden with 128,901
inhabitants in 2019. HAI is an ongoing primary preven-
tion study conducted at a single clinic with the aim of
identifying traditional and potentially new risk factors
for CVD, falls, and fractures among 70-year-olds in
Umeå. The eligibility criteria are residence in Umeå mu-
nicipality and an age of exactly 70. There are no exclu-
sion criteria, and population registers are used for
recruitment. From the total number of 70-year-olds liv-
ing in Umeå, around 70% have chosen to participate in
the study since it was initiated in May 2012 [23]. For the
present analysis, all HAI participants during May 2012–
October 2017 with available PA measurements and who
were free from diabetes at baseline were included. The
HAI study and the present analysis were both approved
by the Regional Ethical Review Board in Umeå, Sweden
(no. 07-031M with extensions), and all participants pro-
vided written consent to participate in the study.
Baseline assessment
In HAI, the participants arrived at the clinic after having
fasted for at least 4 h, before they completed a compre-
hensive test battery where multiple parameters of health
were evaluated. Five trained research nurses collected all
data with the support of two chief physicians (AN and
PN). Waist- and hip circumference were measured using
a measuring tape. Body height and weight were mea-
sured using a stadiometer (Holtain Limited, Crymych,
Dyfed, UK) and digital scale (Avery Berkel HL 120,
Taiwan), whereby the body mass index (BMI, kg/m2)
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was calculated. Blood pressure was measured using a
digital automatic blood pressure monitor; Omron M6
Comfort HEM-7221-E (Omron Healthcare, Kyoto,
Japan), after at least 15 min of rest. Fasting blood glucose
was measured using the HemoCue 201 RT system (Radi-
ometer Medical ApS, Denmark). Blood lipids were mea-
sured venously, and the samples were analyzed at the
accredited laboratory at the department of clinical chem-
istry, Umeå University hospital. VAT was measured
using a Lunar iDXA device with the CoreScan applica-
tion (GE Healthcare Lunar, Madison, WI, USA). Partici-
pants reported smoking status and prevalent diabetes.
Finally, all participants were sent home for 1 week with
an accelerometer to assess PA.
Exposure assessment
Daily step count was measured for 1 week using hip-
mounted Actigraph GT3X+ accelerometers (Actigraph,
Pensacola, FL, USA). The participants were instructed to
be normally active during these days and wear the accel-
erometer at all times except for when sleeping, shower-
ing or bathing. The raw accelerometer data were
collected at 30 Hz and filtered using the standard Acti-
graph filter to eliminate non-human accelerations. Using
Actilife software 6.11.3, the raw data were transformed
into counts of movement in 60 s epoch lengths, with the
activity threshold set to > 100 cpm (CPM), and sedentary
time classified as < 100 CPM. Participants were required
to have accumulated ≥10 h wear time/day for ≥4 days to
be included in the analysis, where non-wear time was
identified as periods of ≥ 60 consecutive minutes of 0
counts, with an allowance of maximum 2 min of 0–100
CPM. Step count was determined as per the manufac-
turer’s proprietary algorithm and was based on vertical
accelerations. To calculate mean daily step count (steps/
day), the total number of steps during the registration
period was divided by the number of valid days that each
participant had been wearing the accelerometer. Daily
step count measured over the course of 7 days using the
Actigraph GT3X+ has previously shown to correlate well
to PA energy expenditure as measured by doubly layered
water [24].
Assessment of other variables
Data on diagnoses were collected from the Swedish Na-
tional Patient Register which covers all inpatient care in
Sweden since 1987 and all specialist outpatient care
since 2001. Data on prescribed drugs were obtained
from the Prescribed Drug Register, which covers all pre-
scribed drugs sold at pharmacies in Sweden since July
2005. To identify deaths during follow-up, we obtained
data on all-cause mortality from the Swedish Cause of
Death Register. These three registers are managed by
the Swedish National Board of Health and Welfare.
Socioeconomic data (education, income and marital sta-
tus) were collected from Statistics Sweden.
Ascertainment of diabetes
The outcome of the present study was incident cases of
diabetes until December 31, 2017. Cases of diabetes were
collected from the National Patient Register using the
International Classification of Diseases, 10th ed. diagnos-
tic codes E10 and E11. Diagnosis of diabetes in the Na-
tional Patient Register has a positive predictive value of
79–100% [25].
Data linkage
We sent the HAI data, along with each participant’s
unique personal identity number (issued to all residents
of Sweden upon birth or immigration) to Statistics
Sweden. Statistics Sweden attached the socioeconomic
data and replaced the unique personal identity numbers
with a unique study identifier and sent these unique
study identifiers to the Swedish National Board of
Health and Welfare, who attached the data on diagnoses,
drugs and mortality.
Statistical analysis
To evaluate the association between mean steps/day
(continuous variable) and incident diabetes, we calcu-
lated hazard ratios (HR) and 95% confidence intervals
(CI) using Cox proportional hazard regression models.
An evaluation of the scaled Schoenfeld’s residuals
showed that the proportional hazards assumption was
not violated. Follow-up time was calculated as the num-
ber of days from participation in HAI until diagnosis of
diabetes, or until death. For participants who were nei-
ther diagnosed with diabetes nor died, follow-up time
ended on 31st of December 2017. To test for nonlinear-
ity, a squared term for the exposure was added to the
model. When the model indicated a nonlinear associ-
ation (P < 0.05), the dose-response association was fur-
ther evaluated using a flexible parametric model with
cubic splines in default positions and three degrees of
freedom [26]. Based on this graphic illustration, the as-
sociation of incremental cut-points for daily step count
(dichotomous variable; above/below cut-point) with inci-
dent diabetes was investigated using Cox models in 500-
steps/day increments, in order to determine the cut-
point which best distinguished participants with the low-
est risk of diabetes during the follow-up. Adjustment for
covariates were performed in several steps. The first
model was adjusted only for sex and accelerometer wear
time. The second model was additionally adjusted for
VAT to investigate its potential role as a mediator in the
association between daily step count and diabetes. The
third model was additionally adjusted for sedentary time,
level of education (primary, secondary, post-secondary),
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and a composite variable including other cardiometa-
bolic risk factors and diseases. This composite variable
was defined as the number of the following risk factors
present: anticoagulants; elevated triglycerides (≥ 1.7
mmol/l or lipid-lowering agents); elevated blood pres-
sure (≥ 130/85 mmHg or antihypertensives); and previ-
ous stroke/myocardial infarction/angina pectoris. To
determine possible effect modification by sex, an inter-
action analysis was performed by creating a product
term between sex and daily step count, which was added
to a Cox model adjusted for all covariates listed above.
Next, after we had determined the cut-point at which the
association between daily step count and diabetes was
strongest, we compared the risk of incident diabetes for
participants below this cut-point to participants in categor-
ies of 1000-steps/day increments in Cox models according
to the 1st and 2nd level of adjustment, as described above.
In a supplementary analysis, we also investigated the asso-
ciation between daily step count and diabetes when adjust-
ing for BMI vs VAT, and how each of these were associated
with diabetes when entered simultaneously to the model.
Finally, we conducted a sensitivity analysis to minimize
the potential risk of reverse-causality bias. This bias
could occur due to early cases of diabetes and short
follow-up, and from the fact that a low daily step count
at baseline in some participants may be due to early on-
set, or previous history of disease, as opposed to vol-
itional inactivity. Therefore, we repeated all Cox models
after excluding participants with a follow-up time of < 6
months and participants with history of stroke or myo-
cardial infarction. All analyses were performed using
Stata version 13.0 (StataCorp, College Station, TX, USA)
and SPSS version 25.0 (IBM Corporation, Armonk, NY,
USA). P-values < 0.05 and CIs for the HRs which did not
overlap 1.0 were considered to be statistically significant.
Results
Participant characteristics
During May 2012–October 2017, there were 3618 par-
ticipants in HAI, of which 3291 were free from diabetes.
Of these, an additional 236 were excluded due to ineli-
gible accelerometer data. Thus, the total study cohort
comprised 3055, 70-year-olds (52%, women), with a
mean BMI of 26.2 kg/m2 and a mean fasting blood glu-
cose was 5.5 mmol/l (Table 1). Fewer than 5% had previ-
ously suffered a stroke or myocardial infarction, while 54
and 38% had been prescribed anti-hypertensive medica-
tion and lipid-lowering agents, respectively. Mean steps/
day was 7139 (median 7455).
Risk of diabetes during follow-up
The mean follow-up time was 2.6 (range 0.1–5.6) years.
Diabetes was diagnosed in 81 individuals (26 in women
vs 55 in men), 50 individuals died, and the remaining
2924 individuals were followed until 31st December
2017. The incidence rate (IR) of diabetes was 10.2 per
1000-person-years. Mean steps/day was not associated
with the risk of incident diabetes (P = 0.11) after adjust-
ing for the influence of sex and accelerometer wear time,
however, addition of the quadratic term for steps/day to
the model suggested that the association was nonlinear
(Pnonlinearity = 0.01). Subsequently, the dose-response as-
sociation was evaluated graphically using a flexible para-
metric model with three degrees of freedom. As shown
by the dose-response trajectory (Fig. 1), the greatest
benefit of a higher daily step count was observed at the
lower end of the activity range. From around 6000 steps/
day the risk appeared to decrease at a slower rate, before
leveling off at around 8000 steps/day. Based on this fig-
ure, we investigated which stepping cut-point that best
discriminated participants with lower risk of diabetes.
Thus, we investigated the association between different
cut-points for steps/day with incident diabetes starting
at 4000 steps/day up to 6000 steps per day (Table 2).
After adjusting for sex and accelerometer wear time, the
cut-point at which the association between daily step
count and diabetes was strongest was at a cut-point of
4500 steps/day. Specifically, participants taking ≥ 4500
steps/day had 59% lower risk of incident diabetes com-
pared to participants taking fewer steps (HR, 0.41, 95%
CI, 0.25–0.66). Further adjustment for VAT attenuated
the association (HR, 0.64, 95% CI, 0.38–1.06), and the
association was similar in model 3 after further adjust-
ment for sedentary time, education and other cardiomet-
abolic risk factors and diseases (HR, 0.58, 95% CI, 0.32–
1.05). Other significant covariates in model 3 included
VAT (HR, 1.77, 95% CI, 1.45–2.16 per 1 standard devi-
ation [SD, 921 g] greater VAT) and other cardiometa-
bolic risk factors and diseases (HR, 1.30, 95% CI, 1.06–
1.59 per additional risk factor present). The association
was not different in men and women Pinteraction = 0.8).
Next, we investigated the association between daily
step count and diabetes by comparing participants in
categories of 1000-steps/day increments compared to
participants below the cut-point of 4500 steps/day
(Fig. 2). These analyses suggested a similar pattern, that
is, the most pronounced benefit of a higher daily step
count occurs early on the spectrum. Specifically, the as-
sociations for higher cut-points ranging from 5500
steps/day until 9500 steps/day were similar to the associ-
ation for the cut-point of 4500 steps/day (Fig. 2). Again,
adjusting for VAT attenuated the associations.
The supplementary analysis showed that adjusting ei-
ther for BMI or VAT resulted in similar associations be-
tween daily step count and diabetes (Additional file 1).
However, when entering both variables simultaneously
to the model, BMI was no longer associated with dia-
betes (HR, 1.06, 95% CI, 0.98–1.14) whereas VAT was
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strongly and independently associated with increased
risk of diabetes (HR per SD VAT, 1.57, 95% CI, 1.19–
2.07).
Sensitivity analysis
After excluding early cases of diabetes, participants with
a follow-up time < 6months, and participants who had
previously suffered a stroke or myocardial infarction, a
total of 2715 participants and 58 cases of diabetes were
included in the sensitivity analysis. The results of this
analysis confirmed the results from the main analysis.
Specifically, there was a significant association between
the cut-point 4500 steps/day and incident diabetes after
adjusting for sex and accelerometer wear time (HR, 0.53,
95% CI, 0.29–0.96), while further adjusting for VAT at-
tenuated the association (HR, 0.75, 95% CI, 0.40–1.40).
In model 3, the association was slightly stronger and
remained non-significant (HR, 0.63, 95% CI, 0.31–1.29).
Discussion
In this prospective cohort study, we observed an inverse
nonlinear dose-response association between daily step
count and incident diabetes in community-dwelling 70-
year-olds. There was initially a steep decline in relative
risk of diabetes with more steps per day, until around
6000 steps/day from where the risk decreased at a slower
rate, before it leveled off at around 8000 steps/day. It
was also found that a threshold of 4500 steps/day was
best at discriminating participants with lower risk of dia-
betes, where 70-year-olds who took ≥ 4500 steps/day
had around 60% lower risk of incident diabetes com-
pared to those taking fewer steps. However, the associ-
ation was attenuated after adjusting for VAT.
Today, a lay belief is that one needs to take 10,000
steps every day in order to stay healthy, despite that the
scientific evidence to support this statement is weak. On
the contrary, a compelling body of evidence shows that
compared to being inactive, performing any amount of
PA is associated with health benefits, as shown in meta-
analyses for the outcome of diabetes, cardiovascular
mortality and all-cause mortality [27–29]. Interestingly,
Table 1 Participant characteristics of the study cohort comprising
3055, 70-year-old men and women who participated in the
Healthy Ageing Initiative during May 2012–October 2017
Age, years 70.5 (0.1)
Female sex, n (%) 1589 (52.0)
Currently smoking, n (%) 119 (3.9)
Body mass index, kg/m2 26.2 (4.0)
Waist circumference, cm 93 (12)
Visceral adipose tissue, grams 1423 (921)
Systolic blood pressure, mmHg 139 (17)
Diastolic blood pressure, mmHg 82 (9)
Low-density lipoprotein cholesterol, mmol/l 3.4 (1.0)
High-density lipoprotein cholesterol, mmol/l 1.6 (0.5)
Total cholesterol, mmol/l 5.6 (1.2)
Triglycerides, mmol/l 1.3 (0.6)
Fasting blood glucose, mmol/l 5.5 (0.8)
Steps/day 7193 (3072)
Sedentary time, hours/day 8.8 (1.3)
Annual disposable income at age 60, 1000
Swedish kronor
246 (176)





Missing data, n 4
Marital status,a n (%)
Married 2036 (66.6)
Never married 253 (8.3)
Widowed 240 (7.9)
Divorced 526 (17.2)
Missing data, n 0
Diagnoses, n (%)
Stroke 98 (3.2)
Myocardial infarction 119 (3.9)
Angina pectoris 205 (6.7)
Fracture 487 (15.9)
Rheumatoid arthritis 65 (2.1)
Renal failure 23 (0.8)
Chronic obstructive pulmonary disease 50 (1.6)
Parkinson’s disease 21 (0.7)
Depression 601 (19.7)
Alcohol intoxication 26 (0.9)
Cancer 562 (18.4)
Prescribed drugsb, n (%)
Antihypertensives 1649 (54.0)
Lipid-lowering agents 1160 (38.0)
Table 1 Participant characteristics of the study cohort comprising
3055, 70-year-old men and women who participated in the






Data are presented as means (standard deviation) unless stated otherwise
aEducation and marital status recorded in the calendar year before the
baseline date
bPrescribed drugs filled since July 2005
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although self-reported walking has previously been asso-
ciated with lower risk of diabetes [18], a recent meta-
analysis was unable to definitely characterize the associ-
ation between daily step count and dysglycemia, partly
due to the limited number of studies on this topic [29].
This conclusion confirmed what was highlighted in the
2018 report by the US Physical Activity Guidelines Ad-
visory Committee, which urged researchers to investi-
gate the link between step volume and health outcomes
[22]. Thus, the results of the present study provide im-
portant knowledge and evidence to the field by showing
that a higher daily step count is associated with lower
risk of incident diabetes in older adults. In particular,
our findings highlight a distinct benefit of daily step
counts far below 10,000 steps/day, as our results suggest
that the greatest benefits occur when moving away from
being inactive to increasing daily activity by even a slight
amount. This is supported by the results from two previ-
ous prospective studies which observed that even small
increments in steps per day were indeed significantly as-
sociated with lower risk of incident diabetes in individ-
uals with impaired glucose tolerance [30], and with
incident dysglycemia in individuals with normal glucose
tolerance [31]. Another important finding of the present
study was that the association of daily step count with
incident diabetes was independent of sedentary time. Be-
cause older adults are sedentary for a majority of their
awake time [32], the present findings may have momen-
tous value for sedentary older adults in particular, as to
them, an initial goal of at least 4500 steps/day is likely
far more attainable than 10,000/day.
As mentioned previously, a threshold of 4500 steps/
day was best at discriminating participants with lower
risk of diabetes in the present cohort. Participants who
took ≥ 4500 steps/day had around 60% lower risk of
incident diabetes compared to those who took fewer
steps, which was attenuated to around 40% after adjust-
ing for VAT, as well as additional covariates. When we
further investigated the risk of diabetes for participants
in higher categories of steps/day, from 5500 until 9500,
compared to those below 4500, the results were similar.
Our study may have had limited possibility to detect
other significant thresholds due to insufficient statistical
power, as the number of cases was small, still our find-
ings are similar to those observed in a recent study with
a larger sample. Lee et al. studied the association of step
volume with all-cause mortality in 16,741 older women,
with 504 events of death during 4.3 years of follow-up
[33]. They found that a cut-point of 4400 steps/day was
associated with the largest risk reduction, and from
there, the risk decreased at a slower rate until it leveled
off at around 7500 steps/day. This pattern is strikingly
similar to the one observed in the present study. To-
gether, the encouraging findings from the present study,
supported by the previous research, indicates that a daily
step count far below 10,000 steps/day may have substan-
tial benefits related to diabetes risk in older adults.
The mechanisms by which PA could influence the risk
of diabetes are numerous. For example, PA increases
oxidative capacity and promotes insulin-sensitivity and
insulin-independent uptake of blood glucose to the
working musculature by translocation of glucose trans-
porters, namely GLUT4, to the cell membrane [34–36].
There are also mediating pathways, such as through fat
loss. Obesity strongly increases the risk of diabetes in
older people [37], and in the present study we found that
VAT was a strong risk factor for diabetes in older adults,
and partly mediated the association between daily step
count and diabetes. This extends the findings from a
previous study which found that fat loss mediated the
association of daily step count with insulin-sensitivity
[38]. There are several potential explanations to the
strong link between VAT and cardiometabolic abnor-
malities [11]. For example, VAT is characterized by high
lipolytic activity and has a pro-inflammatory profile, as
expressed by its high infiltration of macrophages and the
production and secretion of pro-inflammatory cytokines
[39, 40]. Given its location, VAT is drained through the
portal vein, which may increase the deposition of free
fatty acids and pro-inflammatory cytokines in the liver,
eventually contributing to hyperglycemia, insulin resist-
ance, and dyslipidemia [39, 40]. In addition, greater VAT
is associated with lower levels of adiponectin, which has
beneficial effects on insulin sensitivity [39, 40]. Interest-
ingly, we also found that VAT remained strongly associ-
ated with diabetes independent of BMI and daily step
count. This extends the findings from previous studies
showing that VAT is associated with impaired glucose
tolerance and diabetes independent of BMI [41–43].
Fig. 1 Dose-response association between mean daily step count
and incident diabetes. The shaded area represents 95% confidence
intervals using a reference of 7445 steps/day which was the median
amount of steps/day in the cohort
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Table 2 Hazard ratios for incident diabetes in the study cohort according to different cut-points for daily step count
Stepping cut-points No. of participants IR Hazard ratio (95% CI)
Model 1a Model 2b Model 3c
≥ 4000 steps/d 2707 9.0
vs 0.48 (0.27–0.83) 0.81 (0.45–1.45) 0.79 (0.41–1.53)
< 4000 steps/d 348 19.6
≥4500 steps/d 2557 8.2
vs 0.41 (0.25–0.66) 0.64 (0.38–1.06) 0.58 (0.32–1.05)
< 4500 steps/d 498 21.0
≥ 5000 steps/d 2399 8.3
vs 0.50 (0.31–0.80) 0.77 (0.47–1.27) 0.75 (0.43–1.32)
< 5000 steps/d 656 17.4
≥ 5500 steps/d 2240 8.2
vs 0.55 (0.35–0.88) 0.85 (0.52–1.38) 0.84 (0.48–1.45)
< 5500 steps/d 815 15.6
≥ 6000 steps/d 2040 8.3
vs 0.62 (0.39–0.96) 0.95 (0.59–1.54) 0.93 (0.54–1.60)
< 6000 steps/d 1014 14.1
Abbreviations: CI Confidence interval, IR Incidence rate per 1000 person-years
aadjusted for sex and accelerometer wear time
badditionally adjusted for visceral adipose tissue
cadditionally adjusted for sedentary time, level of education, elevated triglycerides, elevated blood pressure, antihypertensives, lipid-lowering agents,
anticoagulants, myocardial infarction, stroke and angina pectoris
Fig. 2 Association between different cut-points of daily step count and incident diabetes. Hazard ratios and 95% confidence intervals are derived
from Cox regressions. Model 1 was adjusted for sex and accelerometer wear time and model 2 was additionally adjusted for visceral adipose
tissue. Abbreviations: CI, confidence interval
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Because ageing is linked to an increase in VAT [44], in-
terventions aiming to mitigate the rising diabetes preva-
lence in older people may need to be tailored carefully
to effectively promote daily PA at a sustainable level,
while at the same time reduce VAT.
The findings from the present study may have import-
ant implications for clinical practice with respect to the
rise in wearable technology, and that the use of devices
that can track daily steps is increasing also in older
people [20]. This would not only apply to large-scale PA
surveillance, but also for wide distribution of PA inter-
ventions, as wearable devices have the potential to facili-
tate behavior change [45]. Based on several meta-
analyses, short-term interventions using step counters
have been shown to increase daily steps by 2000–2500
steps/day, with favorable effects also on body weight and
blood pressure [46–48]. With respect to the outcome of
diabetes, it is interesting that a previous study which
provided 3 months of light-intensity walking of around
5500 steps/day, improved insulin-resistance and reduced
VAT [49]. There are also indications that significant
changes in daily step count from short-term interven-
tions may persist in both adults and older adults even 4
years after the intervention [50]. Assuming that add-
itional studies investigate the association between daily
steps and health outcomes, with subsequent pooling of
their results, the use of wearable devices for tracking
daily steps and providing step promoting interventions
may eventually become an important and integrated
working method in medical care. Especially in terms of
management and prevention of non-communicable dis-
ease such as diabetes.
Limitations and strengths
There are several methodological aspects of this study
that should be addressed. First, the observational design
does not allow causal inferences to be made, although
randomized trials have previously proven the effective-
ness of lifestyle interventions on diabetes [14, 15]. The
relatively short follow-up time in the present study may
have increased the risk of bias due to reverse causation,
however the associations were confirmed in a sensitivity
analysis excluding early cases and participants with short
follow-up as well as previous CVD. Still, residual con-
founding may remain as it has previously been suggested
that at least 5 years of follow-up need to be excluded to
minimize reverse-causality bias [51]. Next, although the
Swedish National Patient Register includes all cases of
diabetes from inpatient- and secondary outpatient care,
it does not include primary care data, meaning that the
incidence of diabetes in the present study may have been
underestimated. The few cases also prohibited us from
performing extensive subgroup analyses. For instance,
stratification based on sex and VAT would have been
interesting as we previously observed that the higher
prevalence of diabetes in older men compared to women
was related to the larger amount of VAT that older men
carry [42]. It is also worth mentioning that while similar
studies often analyze the associations in multiple cat-
egories, this was not deemed suitable in the present
study given the few cases as this would compromise the
statistical power of our analyses. It would also limit the
possibility to include the same number of covariates,
which would be a clear disadvantage given that we had
access to a vast number of objectively measured parame-
ters including data from national registers with high pre-
cision. Finally, it should be mentioned that the
Actigraph GT3X+ may result in a slight underestimation
of step count, but still correlates strongly with other
commercial activity devices on the market [52].
The present study also has several strengths including
its prospective design, the large population-based sample
with no exclusion criteria, and the inclusion of several
important covariates, all of which were objectively
assessed. For example, VAT was measured using DXA,
and education, prescribed drugs and medical history
were all obtained from national registers. Another
strength is the objective assessment of daily step count,
which not only has high translational potential, but is
also a more accurate measure in contrast to self-
reported PA, as the latter may lead to biased estimations.
For example, in a previous study based on the same
population who constituted the present cohort, self-
reported PA was more than twice that of objectively
measured PA [22], and a recent meta-analysis found the
association of objective PA with mortality to be twice as
strong as what has previously been found in studies
using self-reported measures [27]. Together, the above-
mentioned factors increase both the internal and exter-
nal validity of our findings.
Conclusions
In summary, this study shows that a higher daily step
count is associated with lower risk of incident diabetes
in community-dwelling 70-year-olds in a nonlinear
dose-response fashion.
The greatest benefits occur at the lower end of the ac-
tivity range, and far below 10,000 steps/day, with a cut-
point of 4500 steps/day found to best discriminate par-
ticipants with a lower risk of diabetes. The association is
independent of sex, education, sedentary time, and car-
diometabolic risk factors and diseases, although VAT ap-
pears to partly mediate the association. With the
limitation of being an observational study, these findings
suggest that the greatest benefit of increasing physical
activity in relation to the risk of diabetes in older adults
is observed when moving from being inactive to being
slightly active, and that even a modest increase in daily
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physical activity is beneficial. Because the association
was independent of sedentary time, the results may have
implications for sedentary older adults in particular. Fi-
nally, as VAT was a mediator in the association, lifestyle
interventions aiming to prevent diabetes in older adults
should apart from promoting physical activity also aim
to prevent and reduce central obesity.
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